201 related articles for article (PubMed ID: 27956807)
1. Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data.
Silvestri C; Bartolacci S; Pepe P; Monnini M; Voller F; Cipriani F; Stasi C
World J Gastroenterol; 2016 Nov; 22(44):9829-9835. PubMed ID: 27956807
[TBL] [Abstract][Full Text] [Related]
2. Management of hepatitis C virus infection in childhood.
Galoppo M; Galoppo C
Ann Hepatol; 2010; 9 Suppl():98-102. PubMed ID: 20714004
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
Sagnelli E; Stroffolini T; Sagnelli C; Cacopardo B; Andriulli A; Babudieri S; Coppola N; Gaeta GB; Almasio PL
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):676-681. PubMed ID: 29465473
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
5. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
6. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
7. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
[TBL] [Abstract][Full Text] [Related]
8. Clinical Findings of HCV Chronic Infection in Undocumented Immigrants and Low-Income Refugees in Three Areas of Southern Italy.
Sagnelli E; Alessio L; Sagnelli C; Gualdieri L; Pisaturo M; Minichini C; Di Caprio G; Starace M; Onorato L; Scotto G; Macera M; Coppola N
Ann Hepatol; 2018; 17(1):47-53. PubMed ID: 29311411
[TBL] [Abstract][Full Text] [Related]
9. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
Selvapatt N; Habibi MS; Brown A
J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
[TBL] [Abstract][Full Text] [Related]
10. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and outcome of post-transfusion hepatitis C acquired at different ages and detected in look-back screening.
Millbourn C; Psaros Einberg A; Lindh G; Hökeberg I; Fischler B; Lindahl K
Scand J Gastroenterol; 2018; 53(7):870-875. PubMed ID: 29909701
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
13. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
[TBL] [Abstract][Full Text] [Related]
15. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
16. HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C.
Grigorescu M;
J Gastrointestin Liver Dis; 2009 Mar; 18(1):45-50. PubMed ID: 19337633
[TBL] [Abstract][Full Text] [Related]
17. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
18. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island.
Karatapanis S; Tsoplou P; Papastergiou V; Vasiageorgi A; Stampori M; Saitis I; Tsitsopoulos E; Lisgos P; Skorda L; Ketikoglou I; Goulis I
J Med Virol; 2012 Feb; 84(2):223-8. PubMed ID: 22170541
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit.
Bert F; Rindermann A; Abdelfattah MA; Stahmeyer JT; Rossol S
Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1246-52. PubMed ID: 27439034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
